5777 E. Mayo Blvd.
Phoenix, AZ 85054
United States
Cholangiocarcinoma; IDH1 mutation; Ivosidenib; Phase 3 study
FGR2, fusion; rearrangement; pemigatinib; INCB054828; intrahepatic cholangiocarcinoma; cholangiocarcinoma; biliary tract cancer